Our papers and patents

Model Building and Initial Validation

DetermaIO

Nielsen, T.J., et al., A novel immuno-oncology algorithm measuring tumor microenvironment to predict response to immunotherapies. Heliyon, 2021. 7(3): p. e06438.

TNBCType 101 gene algorithm

Ring, B.Z., et al., Generation of an algorithm based on minimal gene sets to clinically subtype triple negative breast cancer patients. BMC Cancer, 2016. 16: p. 143.

Mammostrat

Ring, B.Z., et al., Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J Clin Oncol, 2006. 24(19): p. 3039-47.

Pulmotype

Ring, B.Z., et al., A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol, 2009. 22(8): p. 1032-43.

Additional Validation and Use Cases

DetermaIO

Antoniotti, C., et al., An Immune-Related Gene Expression Signature Predicts Benefit from Adding Atezolizumab to FOLFOXIRI plus Bevacizumab in Metastatic Colorectal Cancer. Clinical Cancer Research, 2023. 29(12): p. 2291-2298.

Dugo, M., et al., Abstract P2-07-12: Triple negative breast cancer subtypes and early dynamics of the 27-gene IO score predict pCR in the NeoTRIPaPDL1 trial. Cancer Research, 2022. 82(4_Supplement): p. P2-07-12-P2-07-12.

Seitz, R.S., et al., Translation of the 27-gene immuno-oncology test (IO score) to predict outcomes in immune checkpoint inhibitor treated metastatic urothelial cancer patients. Journal of Translational Medicine, 2022. 20(1): p. 370.

Iwase, T., et al., A Novel Immunomodulatory 27-Gene Signature to Predict Response to Neoadjuvant Immunochemotherapy for Primary Triple-Negative Breast Cancer. Cancers (Basel), 2021. 13(19).

Ranganath, H., et al., Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer. BMC Cancer, 2022. 22(1): p. 407.

Nielsen, T.J., et al., The 27-gene IO score is associated with efficacy of PD-1/L1 inhibitors independent of FGFR expression in a real-world metastatic urothelial carcinoma cohort. Cancer Immunol Immunother, 2023. 72(7): p. 2075-2086.

Saltman, D.L., et al., Characterization of the tumor immune-microenvironment of adenocarcinoma of lung with a metastatic lesion in the pancreas treated successfully with first-line, single-agent pembrolizumab. Ther Adv Med Oncol, 2021. 13.

TNBCType 101 gene algorithm

Wang, X.Q., et al., Spatial predictors of immunotherapy response in triple-negative breast cancer. Nature, 2023. 621(7980): p. 868-876.

Stecklein, S.R., et al., Dual Prognostic Classification of Triple-Negative Breast Cancer by DNA Damage Immune Response and Homologous Recombination Deficiency. JCO Precision Oncology, 2023(7): p. e2300197.

Masuda, H., et al., Changes in Triple-Negative Breast Cancer Molecular Subtypes in Patients Without Pathologic Complete Response After Neoadjuvant Systemic Chemotherapy. JCO Precision Oncology, 2022(6): p. e2000368.

Mammostrat

Bartlett, J.M., et al., Mammostrat as an immunohistochemical multigene assay for prediction of early relapse risk in the tamoxifen versus exemestane adjuvant multicenter trial pathology study. J Clin Oncol, 2012. 30(36): p. 4477-84.

Bartlett, J.M., et al., Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. Breast Cancer Res, 2010. 12(4): p. R47.

Patent Filings

WO2022031630, Seitz, Robert Scott, Hout, David, Nielsen, Tyler Jon, Schweitzer, Brock Lloyd, Ring, Brian Z., Ross, Douglas T., CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS

WO2023150194A2, Robert Scott Seitz, Brian Z. Ring Catherine Cronister, David Hout, Tyler Jon Nielsen, Brock Lloyd Schweitzer, Douglas T. Ross CLASSIFYING TUMORS AND PREDICTING RESPONSIVENESS (Expanded claims)

WO2005017530, Ring, Brian Z., Ross, Douglas T., Seitz, Robert S, REAGENTS AND METHODS FOR USE IN CANCER DIAGNOSIS, CLASSIFICATION AND THERAPY

WO2005085863, Ross, Douglas T. Ring, Brian Z., Seitz, Robert S., BIOMARKER:COMPOUND CORRELATIONS IN CANCER DIAGNOSIS AND THERAPY

WO2009117004A1, Brian Z. Ring, Douglas T. Ross, Robert S. Seitz, REAGENTS AND METHODS FOR USE IN HEAD AND NECK CANCER DIAGNOSIS, CLASSIFICATION AND THERAPY